Prometheus Laboratories has launched the first serogenetic test that can predict a patient’s risk of developing Crohn’s disease complications.
Prometheus’s Crohn’s prognostic test uses six serologic markers and three genetic markers to provide the physicians with a personalised serogenetic profile for each patient.
The test will enable physicians to quantify patients based on their risk of developing disease complications, and would assist them in determining optimal treatment strategies.
Director of the IBD Pediatric Center at Cedars Sinai Medical Center in Los Angeles Marla Dubinsky said the test may help physicians develop a more individualised treatment plan for each patient and help them explain the risk / benefit ratio of these treatments to their patients and their families.
Crohn’s disease is a chronic disorder that involves inflammation of the digestive / gastrointestinal track, and an estimated 400,000 and 600,000 individuals in North America are affected by this disease.
Related Companies
